Non-endocrine systemic therapies in advanced breast cancer

European Journal of Cancer, Supplement

Volumn 1, Issue 6 SPEC. ISS., 2003, Pages 287-298

  Piccart, Martine J ^a   Bernard Many, Chantal ^a   Cardoso, Fatima ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PARACETAMOL; PETHIDINE; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 5144224152     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)90033-4     Document Type: Conference Paper

References (30)

1. Cardoso F., Di Leo A., Lohrisch C., et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol. 13:2002;197-207
2. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 344:2001;783-792
3. Findlay B.P., Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 2:(3):1998;140-146
4. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol. 6:1988;679-688
5. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol. 9:1991;305-312
6. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol. 18:2000;3115-3124
7. Bernard-Marry C., Cardoso F., Piccart M.J. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer. 2003;. in press
8. Nabholtz J.M., Senn H.J., Bezwoda W.R., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 17:1999;1413-1424
9. Sjöström J., Blomqvist C., Mouridsen H., et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 35:1999;1194-1201
10. Bonneterre J., Roche H., Monnier A., et al. Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. 87:2002;1210-1215
11. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 20:2002;2812-2823
12. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 17:1999;2341-2354
13. Nabholtz J., Falkson G., Campos D., et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. 2nd ed. Proc Am Soc Clin Oncol. 18:1999;127a
14. Mackey J.R., Paterson A., Dirix L.Y., et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). 2nd ed. Proc Am Soc Clin Oncol. 21:2002;35a
15. Bishop J.F., Dewar J., Toner G.C., et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 17:1999;2355-2364
16. Paridaens R., Biganzoli L., Bruning P., et al. Paclitaxel versus doxorubicin as first line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with crossover. J Clin Oncol. 18:2000;724-733
17. Sledge G.W., Neuberg D., Ingle J., et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer (MBC): an Intergroup trial (E1193). J Clin Oncol. 21:2003;588-592
18. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol. 19:2001;1707-1715
19. Biganzoli L., Cuffer T., Bruning R., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as firstline chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 20:2002;3114-3121
20. Luck H., Thomssen C., Untch M., et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. 2nd ed. Proc Am Soc Clin Oncol. 19:2000;73a
21. Carmichael J. UKCCCR Trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol®(ET) in the first line treatment of women with metastatic breast cancer (MBC). 2nd ed. Proc Am Soc Clin Oncol. 20:2001;22a
22. Joensuu H., Holli K., Heikkinen M., et al. Combination chemotherapy versus single agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 16:1998;3720-3730
23. Norris B., Pritchard K.I., James K., et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 18:2000;2385-2394
24. Ross J., Fletcher J.A. The Her-2/Neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist. 3:1998;237-252
25. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal anti-body in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:1999;2639-2648
26. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol. 20:2002;719-726
27. Di Leo A., Cardoso F., Scohy S., Piccart M.J. Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer. Naboltz J.M., Tonkin K., Reese D.M., Aapro M.S., Buzdar A.U. Breast Cancer Management - Application of Clinical and Translational Evidence to Patient Care. 2nd ed. :2003;367-380 Lippincott Williams & Wilkins
28. Cardoso F., Piccart M.J., Durbecq V., Di Leo A. Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer. 3:(4):2002;247-259
29. Sorlie T., Peron C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Actad Sci USA. 98:2001;10,869-10,874. (19)
30. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol. 20:2002;3628-3636